Trial Profile
MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Oct 2018
Price :
$35
*
At a glance
- Drugs Deoxycholic acid (Primary)
- Indications Subcutaneous fat disorders
- Focus Registrational; Therapeutic Use
- Acronyms REFINE-1
- Sponsors Kythera Biopharmaceuticals
- 11 Oct 2018 According to an Allergan media release, data from this study will be presented at the 2018 American Society For Dermatologic Surgery Meeting.
- 01 Jul 2016 According to an Allergan media release, the company has received positive opinion from the Swedish Medical Products Agency (MPA) for deoxycholic acid (BELKYRA) through European decentralised procedure for the treatment of subdermal fullness.
- 08 Mar 2016 Results of a pooled post-hoc analysis from REFINE-1 and REFINE-2 trials presented at the 74th Annual Meeting of the American Academy of Dermatology